Early Convalescent Plasma for High-Risk Outpatients with Covid-19 | NEJM

Early Convalescent Plasma for High-Risk Outpatients with Covid-19 | NEJM

The administration of Covid-19 convalescent plasma to high-risk outpatients within 1 week after the onset of symptoms of Covid-19 did not prevent disease progression. (SIREN-C3PO ClinicalTrials.gov number, NCT04355767. opens in new tab.)

Comments

Popular posts from this blog

Reduced public health measures contributed to deadly COVID-19 surge in the Americas, PAHO Director says - PAHO/WHO | Pan American Health Organization